Neumora Therapeutics, the neuroscience company launched last year in a bid to revitalize a field much of pharma abandoned, is raising a crossover round and considering filing for an IPO this summer, according to two sources with knowledge of the situation.
A Neumora spokesperson declined to comment, citing company policy “to not comment on financing plans or timelines.”
Neumora was created by ARCH Venture Partners and other prominent venture capital firms to reignite the development of new treatments for brain disorders, including anxiety, autism, eating disorders, and neurodegenerative disorders like Alzheimer’s disease. To do this, ARCH decided to go big: It rolled up several existing companies to create Neumora and gave the project the codename RBNC Therapeutics, or Really Big Neuroscience Company. The company raised a $500 million Series A round, including $100 million from Amgen.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect